RECRUITING

Manipulating E-Cigarette Nicotine to Promote Public Health

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial explores the manipulation of e-cigarette (EC) nicotine to promote public health. Researchers are trying to understand and gather information about how the strength, form, and structure of nicotine in products play a significant role in their potential for addiction and how they might affect health risks. The information gained from this study may allow researchers to understand how these aspects of nicotine influence the potential for addiction, how people puff on ECs, how the body processes nicotine, and any potential harmful effects it might have on health. Exploring these specific characteristics of nicotine may also determine if an EC product standard could help identify optimal nicotine levels for users.

Official Title

Manipulating E-Cigarette Nicotine to Promote Public Health

Quick Facts

Study Start:2024-05-20
Study Completion:2027-05-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06448351

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Current exclusive young adult EC user for at least the past 3 months (confirmed by cotinine testing strip) between 21-24 years old with no/minimal history of smoking cigarettes (\< 10 cigarettes in entire life)
  2. * Current older adult smoker (daily use, ≥ 100 cigarettes in entire life) aged 25-65 with interest in trying an EC
  3. * Willing to abstain from all nicotine, tobacco products, and marijuana for at least 12 hours before study visits
  4. * Read and speak English
  1. * Currently attempting to quit nicotine or tobacco products
  2. * Currently pregnant (will be verified with urine pregnancy test), planning to become pregnant, or breastfeeding
  3. * Current daily use of other tobacco products other than ECs or cigarettes (use of \> 10 traditional cigars, cigarillos, or filtered cigars in entire life; use of smokeless tobacco products \> 10 times in entire life; or hookah in the last 30 days)
  4. * Self-reported diagnosis of lung disease including asthma, cystic fibrosis, or chronic obstructive pulmonary disease
  5. * New or unstable cardiovascular disease diagnosed within the past 3 months
  6. * Use of medications that are inducers of CYP2A6 enzyme such as rifampicin, dexamethasone, phenobarbital, and other anti-convulsion drugs

Contacts and Locations

Principal Investigator

Theodore L Wagener
PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center

Study Locations (Sites)

Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
United States

Collaborators and Investigators

Sponsor: Ohio State University Comprehensive Cancer Center

  • Theodore L Wagener, PRINCIPAL_INVESTIGATOR, Ohio State University Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-20
Study Completion Date2027-05-20

Study Record Updates

Study Start Date2024-05-20
Study Completion Date2027-05-20

Terms related to this study

Additional Relevant MeSH Terms

  • Tobacco-Related Carcinoma